scholarly journals Finasteride and Tamsulosin Combination in Benign Prostatic Enlargement in a Tertiary Hospital

2015 ◽  
Vol 53 (197) ◽  
pp. 1-4 ◽  
Author(s):  
Binod Bade Shrestha ◽  
Mikesh Karmacharya
Keyword(s):  
Combination Therapy ◽  
Symptom Score ◽  
Urine Volume ◽  
Tertiary Hospital ◽  
Combination Group ◽  
Benign Prostatic Enlargement ◽  
Residual Urine ◽  
Prostatic Enlargement ◽  
Male Patients ◽  
American Urological Association

Introduction: Due to aging of the general population, prevalence of Benign Prostatic Enlargement is increasing. Symptoms of BPE may vary between the patients. Aim of the study was to analyze and compare the usefulness of combination drugs therapy and monotherapy after a trial period of six months. Methods: Out of 100 male patients aged 45 years and above diagnosed with BPE, 92 were included in the study. Patients were randomized using computer generated random number table. Of which, 47 patients received combination therapy with Tamsulosin plus Finasteride and 45 patients received monotherapy with Tamsulosin once daily at bed time. Results: The baseline demographic variables were comparable in both groups. The decrease in the total American Urological Association symptom score was statistically significant in the combination group (p<0.0001) as compared to monotherapy (p=0.0715) respectively. There was a statistically significant reduction in the residual urine volume with combination therapy (p<0.0001) than in patients with monotherapy (p= 0.1271). Conclusions: The combination therapy is effective in decreasing the irritative and obstructive symptoms in patients with BPE than monotherapy.  Keywords: AUA symptom score; benign prostatic enlargement; finasteride; post voidal residual urine; tamsulosin.

Plasmakinetic Vapor Enucleation of the Prostate with Button Electrode versus Plasmakinetic Resection of the Prostate for Benign Prostatic Enlargement >90 ml: Perioperative and 3-Month Follow-Up Results of a Prospective, Randomized Clinical Trial

2015 ◽  
Vol 95 (3) ◽  
pp. 260-264 ◽  
Author(s):  
Keqin Zhang ◽  
Dingqi Sun ◽  
Hui Zhang ◽  
Qingwei Cao ◽  
Qiang Fu
Keyword(s):  
Urine Volume ◽  
Operation Time ◽  
Urinary Flow ◽  
Benign Prostatic Enlargement ◽  
Effective Technique ◽  
Prostatic Enlargement ◽  
Postvoid Residual Urine ◽  
Maximum Urinary Flow

Objective: To evaluate plasmakinetic vapor enucleation of the prostate (PVEP) with button electrode and plasmakinetic resection of the prostate (PKRP) in patients with urinary symptoms due to benign prostatic enlargement (BPE) >90 ml. Methods: A total of 112 patients with symptomatic BPE were randomly assigned to either PKRP or PVEP prospectively from August 2012 to May 2014 in our department. Perioperative and postoperative data were investigated during a 3-month follow-up. Results: PVEP was significantly superior to PKRP in terms of operation time (63.9 ± 7.7 vs. 78.1 ± 13.6 min, p < 0.001), hemoglobin loss (1.18 ± 0.30 vs. 1.63 ± 0.38 g/dl, p < 0.001), serum sodium decrease (2.9 ± 0.7 vs. 4.3 ± 0.8 mmol/l, p < 0.001), catheterization duration (49.3 ± 12.2 vs. 78.1 ± 14.8 h, p < 0.001) and hospital stay (100.2 ± 28.3 vs. 116.0 ± 29.2 h, p = 0.004). There were no statistical differences in blood transfusion between the two groups. In addition, there were no statistical differences in maximum urinary flow rate, International Prostate Symptom Score, postvoid residual urine volume, quality-of-life score, transient incontinence, and urethral stricture at 3 months postoperatively. Conclusions: PVEP with button electrode is an equally effective technique for treatment of large BPE with PKRP, with more safety and faster recovery. It may become the superior alternative to PKRP for patients with large BPE.

scholarly journals Value of the visual prostate symptom score in evaluation of symptomatic benign prostatic enlargement: prospective study in a Nigerian population

2019 ◽  
Vol 7 (5) ◽  
pp. 1658
Author(s):  
Victor E. Onowa ◽  
Samaila I. Shuaibu ◽  
Idorenyin C. Akpayak ◽  
Chimaobi G. Ofoha ◽  
Christian A. Agbo ◽  
...  
Keyword(s):  
Symptom Score ◽  
University Teaching ◽  
P Value ◽  
Urinary Flow ◽  
Benign Prostatic Enlargement ◽  
Time Period ◽  
Urinary Tract Symptoms ◽  
Prostatic Enlargement ◽  
Nigerian Population ◽  
Maximum Urinary Flow

Background: To evaluate the correlation of Visual Prostate Symptom Score (VPSS) with International Prostate Symptom Score (IPSS) and Maximum Urinary Flow (Qmax). To investigate the effect of educational level on the ability to independently complete the VPSS versus the IPSS and time taken to do so.Methods: Bio data was taken from men with lower urinary tract symptoms (LUTS) due to Benign Prostatic Enlargement (BPE) who presented at the Urology clinic of Jos University Teaching Hospital. They were administered the IPSS questionnaire and VPSS pictogram, which they completed with or without physician assistance and the time taken to do so was noted. They subsequently had uroflowmetry done on same visit and the data was recorded in a structured proforma. Statistical analysis was done using SPSS(R) version 20. Correlation test was done for VPSS, IPSS and Qmax while the paired t-test was used for the average time spent in completing both questionnaires. A p-value <0.05 was considered as significant.Results: Eighty-five men (aged 42 to 94 years) were enrolled in the study. The VPSS correlated significantly with the IPSS in terms of total score (r = +0.684, p<0.001) and QoL (r = +0.570, p<0.001), as well as with the Qmax (r = -0.222, p = 0.041). A greater proportion (21.2%) of men with limited education could complete the VPSS without physician assistance as compared to the IPSS (6.0%) and the average time taken to complete the VPSS (170.51 seconds) was significantly shorter than the time taken to complete the IPSS (406.42 seconds).Conclusions: The VPSS correlates significantly with the IPSS and Qmax. It can be completed without physician assistance by a greater proportion of men with limited education within a shorter time period.

scholarly journals Diode laser vaporization of prostate as treatment for benign prostatic enlargement: Initial results of 73 patients with 1 year follow-up

2014 ◽  
Vol 61 (1) ◽  
pp. 21-24
Author(s):  
Miodrag Acimovic ◽  
Dragutin Rafailovic ◽  
Uros Bumbasirevic ◽  
Uros Babic ◽  
Veljko Santric ◽  
...  
Keyword(s):  
Diode Laser ◽  
Intraoperative Complications ◽  
Urine Volume ◽  
Laser Vaporization ◽  
Urinary Flow ◽  
Benign Prostatic Enlargement ◽  
Prostatic Enlargement ◽  
Initial Results

Objective: Our objective is to evaluate the efficacy, safety and 12 month outcome of a 980 nm diode laser with Twister fiber in the treatment of benign prostatic enlargement. Materials and methods: Between February 2011 and January 2013, 73 patients with benign prostatic enlargement had undergone diode laser vaporization of prostate at our institution. The following parameters were assessed at baseline, and after a follow-up period of 3 and 12 months: International Prostate Symptom Score, peak urinary flow rate, post-void residual urine volume, and quality of life score. Results: The procedure was completed successfully in all patients with no intraoperative complications. At 12 months postoperatively the percentage improvements in IPSS was-69.09%, Qmax +197%, PVR-88.54%, and QoL-68.29%. Conclusion: Diode laser vaporization of prostate is safe and effective method for treatment of benign prostatic enlargement.

scholarly journals Selection of AVP-shortage patients as candidates for low-dose oral desmopressin administration.

2020 ◽  
Author(s):  
Takumi Takeuchi ◽  
Kazuki Maki ◽  
Yumiko Okuno ◽  
Mami Hattori-Kato ◽  
Koji Mikami
Keyword(s):  
Symptom Score ◽  
Urine Output ◽  
Low Dose ◽  
Urine Volume ◽  
Urine Osmolality ◽  
Serum Osmolality ◽  
Synthetic Analogue ◽  
Urinary Frequency ◽  
Dose Oral ◽  
Male Patients

Introduction Diabetes insipidus (DI) is characterized by the excretion of large volumes of hypotonic urine and thirst due to an impaired ability to concentrate urine, leading to uncontrolled diuresis, which may cause life-threatening dehydration and electrolyte imbalances. Central DI is caused by the deficient secretion of the posterior pituitary antidiuretic hormone arginine vasopressin (AVP). Desmopressin (Deamino-8-D-AVP, the synthetic analogue of AVP, Minirinmelt) is generally used to treat central DI. Desmopressin orally disintegrating tablets are recently administered to male patients with nocturia. We herein attempted to select male patients with an elevated nocturnal urinary frequency possibly due to a shortage of AVP. These patients may be good candidates for low-dose oral desmopressin administration. Patients and methods Serum and spot urine osmolality, electrolytes, serum creatinine, casual blood glucose, plasma brain natriuretic polypeptide (BNP), and plasma AVP were measured at the same time in 97 elderly male patients with urinary symptoms under free water drinking. The International Prostate Symptom Score, Overactive Bladder Symptom Score, and frequency-volume charts at least twice were also evaluated. Results A binary plot of plasma AVP and serum osmolality indicated a region at which patients had relatively lower AVP considering higher serum osmolality. It was tentatively named the Desmopressin region. Twenty out of 97 (20.6 %) patients were in the Desmopressin region. No significant differences were observed in the frequency of administered urinary drugs or existing co-morbidities between patients in the Desmopressin and non-Desmopressin regions. Daily urine output did not exceed 3 L in any patient. Plasma AVP was lower, while serum osmolality and serum sodium were higher in patients in the Desmopressin region than in those in non-Desmopressin region. Furthermore, urine osmolality was slightly lower in patients in the Desmopressin region. No significant differences were observed in urine volume, urinary frequency, or urination questionnaire scores between both groups. Conclusion AVP-shortage patients may be selected for treatment with oral desmopressin based on measurements of serum osmolality and plasma AVP. After the exclusion of patients with marked hyperglycemia, decreased cardiac, or renal function, low-dose oral desmopressin may be administered to patients with an increased urine output, nocturia, elevated plasma osmolality, and relatively low plasma AVP.

Sign in / Sign up

Export Citation Format

Share Document